Comparative Pharmacology
Head-to-head clinical analysis: BETAPEN VK versus BICILLIN L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPEN VK versus BICILLIN L A.
BETAPEN-VK vs BICILLIN L-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan synthesis, leading to cell lysis.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections; up to 500 mg orally every 4 hours for severe infections.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
None Documented
None Documented
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours with creatinine clearance <10 mL/min.
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
Renal excretion accounts for 20-40% of the dose as unchanged drug via tubular secretion and glomerular filtration; biliary/fecal excretion is minimal (<10%).
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic